HER2-positive
Breast cancer HER2-positive: sequential versus concomitant therapy
... Trastuzumab was initially approved to be used in the adjuvant treatment of early-stage HER2-positive breast cancer. Adjuvant therapies are used as a primary treatment (surgery), whose main goal is to ...
52
For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
... for HER2-positive breast cancer [12– ...pT1aN0M0 HER2-positive women, while the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines 2011 [19] held that the use of ...
7
Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
... Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of HER2. It can potently suppress cancer cells’ growth, proliferation, and survival in direct and indirect manners (2). It is ...
6
Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
... Trastuzumab emtansina (T-DM1) is an antibody-drug conju- gate directed against the HER2 for the treatment of HER2+ mestastatic breast cancer (MBC), who has previously received trastuzumab plus a taxane. ...
5
Rev. Bras. Ginecol. Obstet. vol.36 número8
... with HER2-positive pri- mary breast carcinomas diagnosed in 2007 and 2008 were selected from the iles of the Consultoria em Patologia (Botucatu, São Paulo), a major reference laboratory in Brazil that ...
7
Rev. Assoc. Med. Bras. vol.58 número2 en v58n2a13
... he latter study did not include the evaluation of the Ki-67 cell proliferation index, and instead considered oth- er markers for classiication of subtypes, such as epidermal growth factor receptor (EGFR) and cytokeratin ...
10
HER2 targeted molecular MR imaging using a de novo designed protein contrast agent.
... high HER2 expression and a breast cancer cell line MDA-MB-231 with low expression level of ...low HER2 expression was implanted in the left flank of the same mouse for direct comparison ...point, ...
9
Mammakarzinom: Spezifische Aspekte der Therapie kleiner HER2-positiver Tumore
... operable HER2-positive breast ...N9831 HER2- positive adjuvant breast cancer ...Her2neu positive early breast cancer ...axillary-node- positive breast cancer: results of the ...
8
Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama.
... B HER2 negative, luminal B HER2 positive, triple negative, and HER2 ...- HER2 negative ...- HER2 positive and triple negative subtypes ...and HER2 positive ...
10
Vista do Impacto de medicamentos biossimilares utilizados na imunoterapia contra o câncer de mama no Brasil | Brazilian Journal of Natural Sciences
... patients. HER2 is a clinically established therapeu- tic target in therapy against breast malignancy; it is estimated that HER2 overexpression occurs in approximately 20% of breast carcinoma cases; several ...
13
Clinical and molecular characterization of feline mammary carcinomas overexpressing HER2 proto-oncogene (FMC-HER2+) : new strategies for effective diagnostic and cancer therapy
... USA). HER2 immunoreactivity was scored according to the American Society of Clinical Oncology’s recommendations (Wolff et ...as HER2-negative when scored 0 or +1 and HER2-positive if scored as ...
277
HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.
... of HER2 overexpression in advanced CRC patients ...that HER2 served to predict resistance to anti-EGFR monoclonal antibody in patient- derived xenografts from metastatic CRC, leading the authors to suggest ...
9
Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas.
... Interestingly, in patients with low p-Akt1 expression, cytoplas- mic Skp2 expression was significantly associated with DFS and OS of patients with breast carcinoma. In contrast, in patients with high cytoplasmic ...
9
Avaliação dos níveis serológicos de HER-2 : relevância clínica em cadelas com tumores mamários malignos
... Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast [r] ...
117
Clinics vol.68 número5
... of HER2 overexpression in ...both HER2 positivity and HER2-enriched profiles were similar between the pure DCIS and DCIS/IC ...triple- positive profile was predominant in the high-grade pure ...
6
Resposta completa e duradoura em câncer gástrico metastático HER2-positivo
... BANG YJ, VAN CUTSEM E, FEYEREISLOVA A, CHUNG HC, SHEN L, SAWAKI A, LORDICK F, OHTSU A, OMURO Y, SATOH T, ET AL. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of ...
5
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
... with HER2 positive ...on HER2 positive CTCs [21] should not be used to broadly suggest that CTC directed therapeutics is likely to fail, or that anti-HER2 treatments cannot be used in ...
7
Uso de trastuzumabe para o tratamento de mulheres com câncer de mama HER2 positivo:...
... No associations were found between the most frequent adverse events and the sociodemographic and clinical variables of the patients by logistic regression models. Results Part B: Ten patients were included in the study ...
37
Arq. Bras. Cardiol. vol.94 número1
... 19. Slamon DJ, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in ...
5
Arq. Gastroenterol. vol.53 número2
... of HER2 expression with prognosis has been studied in many cancer ...express HER2 and correlate this with clinical characteristics as well as treatment ...for HER2 expression. Five (16%) patients ...
6